Access TOC
Download Data
November 2024
The global miRNA sequencing and assay market size is calculated at US$ 391.73 in 2024, grew to US$ 443.95 million in 2025, and is projected to reach around US$ 1369.11 million by 2034. The market is expanding at a CAGR of 13.33% between 2024 and 2034. miRNAs hold great potential in disease diagnosis and the development of new treatment options, due to which they are highly used in next-generation sequencing.
Unlock Infinite Advantages: Subscribe to Annual Membership
The diverse family of small, non-coding RNA molecules known as tiny RNAs is typically less than 200 nucleotides long. Of these, microRNAs, or miRNAs, have been studied and characterized the most. Next-generation sequencing (NGS), which provides precise, high-throughput profiling of small RNA and miRNA molecules, has revolutionized research on these molecules. Both known and new miRNAs may be found and measured using NGS-based short RNA sequencing, which provides details on how they act in gene regulatory networks and disease pathways. Researchers may also use NGS to look at patterns across different tissue types, developmental phases, or disease states to ascertain the functional importance of miRNA expression patterns.
To better comprehend hidden patterns in vast and complex genome data sets from fundamental and clinical research initiatives, the genomics sector is expanding the use of computational techniques like artificial intelligence and machine learning. CRISPR and other genetic techniques and disease studies may benefit from machine learning analysis. NHGRI is recognizing and defining its distinct position in the intersection of machine learning and genomics research.
For instance,
miRNA’s Potential use as Biomarkers
The variable expression of miRNAs in sick tissues and their differential enrichment in plasma, serum, and other bodily fluids have been demonstrated in a number of studies, which may make them valuable for routine clinical diagnosis. Finding miRNA signatures that are indicative of various diseases, such as cancer, viral infections, disorders of the nervous system, cardiovascular disease, muscular disorders, diabetes, and others, has been the primary focus of research. Several studies have been specifically created to validate miRNAs as biomarkers and elucidate their function in controlling physiological and pathological processes.
Specificity Related Challenges
Following early encouraging findings, it was evident that a number of significant obstacles were impeding the development of miRNA biomarkers. The problem of specificity is the most important of them. Researchers quickly discovered that it might be difficult to distinguish related disorders using circulating miRNA profiles. To overcome this seeming lack of specificity, some researchers are using sophisticated bioinformatics methods. We can find and assess the miRNA pattern with the best prediction value by using machine learning.
Using miRNA as Therapeutics
Understanding how miRNAs function in development and illness, especially cancer, has made them desirable targets and instruments for cutting-edge treatment strategies. Numerous miRNA-targeted treatments have advanced to the clinical stage, such as antimiRs that target miR-122, which have advanced to phase II trials for the treatment of hepatitis, and a mimic of the tumor suppressor miRNA miR-34, which has advanced to phase I clinical trials for the treatment of cancer.
The product and service segment dominated the miRNA sequencing and assay market in 2023. Products include the necessary kits, reagents, solutions, and tools for conducting miRNA sequencing and assays. It is essential to provide high-quality products to get accurate results.
By product & service, the services segment is expected to achieve the fastest CAGR in the miRNA sequencing and assay market during the forecast period of 2024-2034. There are various services associated with miRNA sequencing and assay. Some of the services are quantification of samples, library construction, sequencing, NGS, bioinformatics, data analysis, and data reporting. These services are essential for data storage and analysis for disease diagnosis, treatment, and other purposes.
By technology, the sequencing by synthesis segment held the major share of the miRNA sequencing and assay market in 2023. One of the most popular next-generation sequencing (NGS) technologies in the world is sequencing by synthesis (SBS). The SBS method sequences the tens of millions of clusters on the flow cell surface in parallel using four fluorescently tagged nucleotides.
By technology, the sequencing by oligonucleotide ligation and detection (SOLiD) segment is estimated to achieve the fastest growth rate in the miRNA sequencing and assay market during the predicted timeframe. Because SOLiD sequencing uses dual-reading and two-base encoding, it provides great accuracy. By ensuring that every base is read twice, the two-base encoding scheme lowers mistakes and boosts base calling confidence. When compared to other next-generation sequencing systems, it is more affordable, particularly for applications requiring high precision.
By workflow, the sequencing segment remained dominant in the miRNA sequencing and assay market in 2023 and is estimated to grow at the fastest rate during 2024-2034. In contrast to other types of RNA-seq, miRNA-seq frequently uses input material that has been enriched for short RNAs. miRNA-seq enables researchers to identify previously unidentified miRNAs and investigate tissue-specific expression patterns, illness correlations, and isoforms of miRNAs.
By application, the cancer segment dominated the miRNA sequencing and assay market in 2023. miRNAs have a significant impact on the transformation of cancer cells. Through their targeting of genes implicated in cell-cycle inhibition or tumor formation and progression, miRNAs can act as oncogenes or tumor-suppressor genes. MicroRNAs have been exceedingly promising for cancer detection, prognosis, and treatment ever since they were discovered.
By application, the polyglutamine disease segment is anticipated to grow at the fastest CAGR in the miRNA sequencing and assay market during the predicted period. Recent research has shown that a variety of miRNAs can both function as biomarkers to anticipate neuronal illness states and control the progression of neurodegenerative disorders.
By end-use, the research and academic institutes segment dominated the miRNA sequencing and assay market in 2023. The use of miRNA as biomarkers and as therapeutics is still in the review and study stage. Various academic and research institutes are continuously conducting research to fully explore the potential of miRNA in various healthcare related applications.
By end-use, the pharmaceutical and biotechnology industry segment is estimated to grow at a significant rate in the miRNA sequencing and assay market during the forecast period. Once miRNA-based therapeutics are available after FDA approval, the pharmaceutical and biotechnology industries will use miRNA to develop novel therapeutics for various diseases.
North America dominated the miRNA sequencing and assay market in 2023. The growing use of miRNA sequencing assays to identify a number of serious illnesses in North America is what defines the region. Additionally, the market for miRNA sequencing is expected to develop in North America due to the growing need for customized treatment and the rise in both acute and chronic disorders since miRNA serves as a biomarker for these conditions. One of the main drivers of market expansion is the increasing incidence of chronic illnesses. Regional development is fueled by the existence of several individuals and organizations in this area that take action to increase public knowledge of new and better miRNA sequencing products and technology.
Additionally, government-funded clinics, healthcare networks, the military, and agricultural organizations make extensive use of miRNA sequencing and tests. Consequently, the rise of regional markets is being aided by favorable government policies and investments.
Asia Pacific is expected to host the fastest-growing miRNA sequencing and assay market during the forecast period. Because chronic illnesses are becoming more common, and there is a rising need for tailored medication. The area is a perfect market for miRNA sequencing and assay services since it is home to a sizable population with a variety of genetic origins. The development of precise and reasonably priced miRNA sequencing and test services has been made possible by the growing accessibility of cutting-edge technology, which includes high-throughput assays and next-generation sequencing. This has further fueled the market's expansion in the area.
The market has expanded as a result of growing investments made in research and development by both public and private entities. Additionally, the market in the area is anticipated to be driven by the growing need for miRNA sequencing and assay services in the biotechnology and pharmaceutical sectors.
In March 2024, since its start in the 1970s, genetic sequencing has advanced significantly, according to Dr. Kuo, the CEO of the business. One of the most intriguing new advances in biotechnology is long-read RNA sequencing, which is driving the industry to move away from short-read sequencing. We think that a fresh generation of biotechnology advances might be accelerated by our solution. Its potential is demonstrated by the support of some of the top life science investors in the UK. The money will support our efforts to uncover the hidden realm of RNA and open up fascinating new uses.
By Product & Service
By Technology
By Workflow
By Application
By End-use
By Region
November 2024
November 2024
November 2024
November 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts